-
公开(公告)号：US20090304629A1
公开(公告)日：2009-12-10
申请号：US12351144
申请日：2009-01-09
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07601709B2
公开(公告)日：2009-10-13
申请号：US10774047
申请日：2004-02-06
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
IPC分类号： C07D245/00 , C07D487/00 , A61K31/33 , A01N43/00
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07273851B2
公开(公告)日：2007-09-25
申请号：US10849107
申请日：2004-05-19
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat S. Or
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat S. Or
IPC分类号： A61K38/00
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20100015092A1
公开(公告)日：2010-01-21
申请号：US12505725
申请日：2009-07-20
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07D403/12 , A61K31/497 , C12N9/99 , A61K38/45 , A61K38/48 , A61P31/14
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07368452B2
公开(公告)日：2008-05-06
申请号：US11489011
申请日：2006-07-18
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Gouyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Gouyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
IPC分类号： A61P31/12
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US08236807B2
公开(公告)日：2012-08-07
申请号：US12505725
申请日：2009-07-20
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
IPC分类号： C07D401/12 , C07D409/14 , A61K31/38 , A61K31/395 , A61P31/12
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07718769B2
公开(公告)日：2010-05-18
申请号：US11602586
申请日：2006-11-20
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Sun Or
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Sun Or
IPC分类号： A61K38/00
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20080152622A1
公开(公告)日：2008-06-26
申请号：US12043421
申请日：2008-03-06
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07176208B2
公开(公告)日：2007-02-13
申请号：US10826743
申请日：2004-04-16
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
IPC分类号： C07D401/12 , C07D409/14 , A61K31/38 , A61K31/395 , A61P31/12
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20050261200A1
公开(公告)日：2005-11-24
申请号：US10849107
申请日：2004-05-19
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Or
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Or
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
-
-
-
-
-
-
-
-
搜索结果
254 条记录 (耗时 0.044 秒)
